Information Provided By:
Fly News Breaks for February 24, 2020
Feb 24, 2020 | 06:39 EDT
Chardan analyst Geulah Livshits initiated coverage of Homology Medicines (FIXX) with a Buy rating and $34 price target. In a research note to investors, the analyst says that while HMI-102 faces competition from assets in development by BioMarin (BMRN) and others, she believes Homology's potentially-registrational trial design and internal manufacturing capabilities position the company to move quickly. Homology is well positioned to advance its internal programs, Livshits says, adding that the company does not need gene editing to work in order to see upside.
News For FIXX;BMRN From the Last 2 Days
Mar 3, 2021 | 08:33 EST
BioMarin Pharmaceutical announced that the company has completed full enrollment in a global Phase 2 randomized, placebo-controlled study of vosoritide, an investigational, once daily injection analog of C-type Natriuretic Peptide for children with achondroplasia, the most common form of disproportionate short stature in humans. The 52-week study consists of approximately 70 infants and young children with achondroplasia, aged zero to less than five years old. The study will be followed by a subsequent open-label extension trial where all children receive active treatment. Children in this study will have completed a minimum three- or six-month baseline study to determine their respective baseline growth prior to entering the Phase 2 study. The objectives of the study are to evaluate safety, tolerability, and the effect of vosoritide on growth. The company also plans to augment the height data with assessments including proportionality, functionality, quality of life, sleep apnea, and foramen magnum dimension, as well as the advent of major illnesses and surgeries.
Mar 1, 2021 | 16:17 EST
Stifel analyst Dae Gon Ha initiated coverage of Homology Medicines with a Hold rating and $14 price target. With the next meaningful update by by the end of 2021 and other early-stage programs just entering the clinic near-term, the shares could be range-bound, the analyst tells investors in a research note.